权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Molecular Mechanisms of Dystrophin Expression in Ameliorated Phenotypes

改善表型中肌营养不良蛋白表达的分子机制

基本信息

批准号：
10660396
负责人：
KEVIN M FLANIGAN
金额：
$ 45.44万
依托单位：
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-01-18 至 2027-12-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10660396
关键词：
Address Age Alleles Becker Muscular Dystrophy Biopsy Cell Line Characteristics Clinical Data Dependovirus Development Disease Duchenne muscular dystrophy Dystrophin Exons Family Gene Delivery Genes Genetic Genotype Goals Length Link Longevity Messenger RNA Methods Molecular Muscle Muscular Dystrophies Mutation Mutation Analysis Myoblasts Needles Open Reading Frames Outcome Patients Phenotype Principal Investigator Privatization Prognosis Protein Isoforms Proteins RNA Splicing Reading Frames Retreatment Rod Severities Severity of illness Spectrin Techniques Testing Therapeutic Time Transgenes Variant Viral Packaging Work boys clinical phenotype cohort dystrophinopathy exon skipping functional outcomes gene replacement therapy gene therapy genomic predictors improved outcome insight micro-dystrophin novel patient population patient subsets postnatal protective effect restoration sample archive therapy development transcriptome sequencing vector

项目摘要

Abstract Duchenne muscular dystrophy (DMD) typically results from mutations in the DMD gene that disrupt the open reading frame, resulting in no dystrophin protein, whereas the milder Becker muscular dystrophy (BMD) typically results from mutations that allow expression of a partially functional dystrophin protein. This observation has led to the development of therapies intended to result in expression of internally-deleted, BMD-like dystrophin proteins. Despite the availability of four such commercial therapies for a subset of patients, and the transformative promise of microdystrophin gene therapies that are on the horizon, there are fundamental unanswered questions about the relationship of partial dystrophin expression to patient function—questions that bear on our ability to assess the benefits of therapies, to offer prognosis to families, and to guide approaches to retreatment in gene replacement therapies, among other issues. Furthermore, it will be critical to understand the distinctions between endogenous, lifelong expression of partially functional dystrophins, and therapeutic dystrophins delivered postnatally. Our long-term goal is to understand a fundamental question: How much dystrophin protein—and what kind of partially functional dystrophin, expressed at what time—is enough? Our objective in this project is two-fold. First, we seek to understand in finer detail the molecular parameters of dystrophin expression that result in phenotype amelioration. Second, we seek to develop methods for full-length dystrophin expression from the endogenous DMD gene, which is a possibility for a for a subset of patients, and has the potential for improved outcomes in comparison to microdystrophin. Our central hypothesis is that multiple mechanisms exist to account for variations in disease severity, and that understanding these mechanisms will lead to a better understanding of the durability and long-term benefits of dystrophin restoration therapies. Our rationale is that a detailed exploration of these mechanisms will lead to a better understanding of the long-term outcomes expected from novel gene therapies for DMD.

摘要杜氏肌营养不良症（DMD）通常由DMD基因突变引起，破坏开放阅读框架，导致没有肌营养不良蛋白，而温和的贝克尔肌营养不良症（BMD）通常是由允许部分功能性肌营养不良蛋白这一观察结果导致了治疗的发展以导致内部缺失的BMD样肌营养不良蛋白的表达。尽管有四个这样的商业疗法的一个子集的患者，和变革的承诺，微肌营养不良蛋白基因疗法是在地平线上，有根本的答案关于部分肌营养不良蛋白表达与患者功能关系的问题-问题这关系到我们评估治疗益处的能力，为家庭提供预后，指导基因替代疗法的再治疗方法等问题。此外，理解内源性、终身性和部分功能性肌营养不良蛋白的表达和出生后递送的治疗性肌营养不良蛋白。我们的长期目标是了解一个基本问题：什么样的部分功能性肌营养不良蛋白，在什么时候表达，是足够的？我们的目标是这个项目是双重的。首先，我们试图更详细地了解分子参数，导致表型改善肌营养不良蛋白表达。第二，我们寻求发展从内源性DMD基因表达全长肌营养不良蛋白的方法，对于一个子集的患者的可能性，并有可能改善结果，与microdystrophin相比。我们的中心假设是，存在多种机制，解释疾病严重程度的变化，理解这些机制将导致更好地了解抗肌萎缩蛋白恢复疗法的持久性和长期益处。我们的理由是，详细探讨这些机制将导致更好地了解 DMD新型基因疗法预期的长期结果。